AFMD Affimed NV

Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at two upcoming investor conferences.

Credit Suisse Antibody DayDate: Wednesday, September 7, 2016Time: 10:40 a.m. ETLocation: New York, NY

2016 Wells Fargo Healthcare ConferenceDate: Thursday, September 8, 2016Time: 1:10 p.m. ETLocation: Boston, MA

A live webcast of each conference presentation can be accessed through the “Events” section on the “Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentations will be available from Affimed’s website for 30 days following the respective conference.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

IR Contact:

Caroline Stewart, Head IR
Phone: +1 347 394 6793
E-Mail: IR@affimed.com or c.stewart@affimed.com

Media Contact:

Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 6479 3341
E-Mail: a.alexandru@affimed.com